本项临床试验的目标是评估使用拉米夫定和疫苗联合治疗CHB患者的有效性。方法:选取72例CHB患者(40例HBeAg阳性,32例抗HBe阳性)。所有的患者以100mg/d的剂量接受12个月的拉夫米定治疗,15例患者(9例HBeAg+,6例抗HBe+)在口服拉米夫定的同时皮内注射乙肝疫苗20μg,每两周1次,共12次 The goal of this clinical trial is to evaluate the efficacy of combining lamivudine and a vaccine in the treatment of patients with CHB. Methods: 72 CHB patients (40 HBeAg positive and 32 anti-HBe positive) were selected. All patients were treated with lamivudine for 12 months at a dose of 100 mg / d. Fifteen patients (9 HBeAg +, 6 anti-HBe +) were injected intradermally with 20 μg hepatitis B vaccine every two weeks while oral lamivudine 1 times, a total of 12 times